0001564590-16-019958.txt : 20160525 0001564590-16-019958.hdr.sgml : 20160525 20160525172617 ACCESSION NUMBER: 0001564590-16-019958 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20160524 ITEM INFORMATION: Submission of Matters to a Vote of Security Holders FILED AS OF DATE: 20160525 DATE AS OF CHANGE: 20160525 FILER: COMPANY DATA: COMPANY CONFORMED NAME: KEMPHARM, INC CENTRAL INDEX KEY: 0001434647 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 205894398 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36913 FILM NUMBER: 161675544 BUSINESS ADDRESS: STREET 1: 2656 CROSSPARK ROAD, SUITE 100 CITY: CORALVILLE STATE: IA ZIP: 52241 BUSINESS PHONE: 319-665-2575 MAIL ADDRESS: STREET 1: 2656 CROSSPARK ROAD, SUITE 100 CITY: CORALVILLE STATE: IA ZIP: 52241 FORMER COMPANY: FORMER CONFORMED NAME: KEMPHARM INC DATE OF NAME CHANGE: 20080507 8-K 1 kmph-8k_20160525.htm 8-K kmph-8k_20160525.htm

 

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 25, 2016 (May 24, 2016)

 

KEMPHARM, INC.

(Exact name of Registrant as Specified in Its Charter)

 

 

Delaware

001-36913

20-5894398

(State or Other Jurisdiction

of Incorporation)

(Commission File Number)

(IRS Employer

Identification No.)

 

 

 

2656 Crosspark Road, Suite 100

Coralville, IA

 

52241

(Address of Principal Executive Offices)

 

(Zip Code)

Registrant’s Telephone Number, Including Area Code: (319) 665-2575

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):

¨

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

Item 5.07          Submission of Matters to a Vote of Security Holders.

 

On May 24, 2016, KemPharm, Inc. (the “Company”) held its 2016 Annual Meeting of Stockholders (the “2016 Annual Meeting”), for the following purposes:

 

 

•

to elect two nominees for director, each to serve until the 2019 Annual Meeting of Stockholders and until his successor has been elected and qualified or until his earlier death, resignation or removal; and

 

 

•

to ratify the selection by the Audit Committee of the Board of Directors of Ernst & Young LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2016.

 

Of the 14,512,263 shares outstanding as of the record date, 12,807,582 shares, or 88.25%, were present or represented by proxy at the 2016 Annual Meeting. At the 2016 Annual Meeting, each of Travis C. Mickle and Danny L. Thompson was re-elected as a director of the Company. The stockholders of the Company ratified the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the Company's fiscal year ending December 31, 2016. The final voting results on each of the matters submitted to a vote of stockholders at the 2016 Annual Meeting were as follows:

 

 

 

 

 

 

 1.

Election of Directors

For

Withheld

Broker Non-Votes

 

Travis C. Mickle

6,975,879

2,188,128

3,643,575

 

Danny L. Thompson

6,976,294

2,187,713

3,643,575

 

 

 

 

 

For

 

Against

 

Abstentions

Broker Non-Votes

2.

Ratification of Ernst & Young LLP as independent registered public accounting firm for the Company's fiscal year ending December 31, 2016

12,292,337

515,245

0

0

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

 

 

KEMPHARM, INC.

 

 

 

 

Date: May 25, 2016

 

By:

/s/ R. LaDuane Clifton

 

 

 

R. LaDuane Clifton

 

 

 

Chief Financial Officer